Immunoproteasome Inhibitor Program AutoImmune / Inflammatory Diseases


  • Selective blockade of immune cells by targeting the immunoproteasome and sparing the constitutive proteasome to inhibit pro-inflammatory cytokine production, aberrant T cell function and effects on antigen presentation

  • Developing selective inhibitors of the immunoproteasome subunits with potential utility in psoriasis, inflammatory bowel disease and other autoimmune diseases

  • We entered into a collaboration agreement with AbbVie for the development of oral immunoproteasome inhibitors

  • The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology for the treatment of inflammation and autoimmune disorders